Achieving Equitable Access in CLL Trials
January 23, 2026
CLL Society has actively promoted equitable access in CLL trials and researched what factors determine the patient’s choice to enroll.
CLL Society has actively promoted equitable access in CLL trials and researched what factors determine the patient’s choice to enroll.
NX-5948 is a novel type of drug, classified as a BTK degrader, and it has shown promising early clinical data.
CLL Society awarded Dr. Matthews Davids a research grant for his project Optimizing Glofitamab Combination Therapy in Richter’s Transformation.
Disparities persist as Blacks, Hispanics, and females are underrepresented in clinical trials for CLL and other blood cancers.
Richter’s transformation is a rare complication of CLL and changes in how clinical trials are conducted might help patients access novel therapies.
Preclinical research shows that LP-168 inhibits BTK in CLL cells regardless of whether resistance mutations exist.
The FDA is revising clinical trials to improve safety, and CLL Society’s Dr. Brian Koffman was asked to serve as the patient representative
A new clinical trial is recruiting patients with relapsed / refractory B-cell cancers to test the safety of a new experimental MALT1 inhibitor.
A new phase 3 clinical trial is testing sonrotoclax, a new BCL2 inhibitor, in combination with zanubrutinib for CLL.